Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Research from University of Zurich in the area of adenocarcinoma described
July 1st, 2008
According to a study from Zurich, Switzerland, " To test the safety of neoadjuvant chemotherapy for resectable pancreatic cancer. Patients and Methods Patients with cytologically proven resectable adenocarcinoma of the pancreatic head were eligible for this prospective phase II trial." "After confirmation of resectability by contrast-enhanced computed tomography (ceCT), positron emission tomography/CT, laparoscopy, and endoscopic ultrasound, patients received four biweekly cycles of gemcitabine 1,000 mg/m(2) and cisplatin 50 mg/m(2). Thereafter, staging was repeated and patients underwent surgery. Quality of life (QoL) and prealbumin serum levels were determined pre-...
Source: Cancer Weekly (2008-07-01)
|
